Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.68 |
| ▸ | RAB9A | P51151 | 4/20 | 0.68 |
| ▸ | POLB | P06746 | 1/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.68 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.41 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.41 |
| ▸ | TAS1R2 | Q8TE23 | 2/20 | 0.41 |
| ▸ | PLA2G7 | Q13093 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13597882 | 0.86 | NPC1 (0.57) | NPC1RAB9APOLBSMN1; SMN2RXFP1 | |
| SCHEMBL22639784 | 0.81 | RAB9A (1.00) | NPC1RAB9APOLBSMN1; SMN2RXFP1 | |
| SCHEMBL1622809 | 0.81 | RAB9A (1.00) | NPC1RAB9APOLBSMN1; SMN2RXFP1 | |
| SCHEMBL5107516 | 0.79 | NPC1 (0.63) | NPC1RAB9APOLBSMN1; SMN2RXFP1 | |
| SCHEMBL13597880 | 0.78 | DEGS1 (0.48) | NPC1RAB9APOLBSMN1; SMN2RXFP1 | |
| SCHEMBL3988851 | 0.78 | ACHE (0.53) | NPC1RAB9APOLBSMN1; SMN2RXFP1 | |
| SCHEMBL13598070 | 0.77 | NPC1 (0.71) | NPC1RAB9APOLBSMN1; SMN2RXFP1 | |
| SCHEMBL5529629 | 0.77 | NPC1 (0.71) | NPC1RAB9APOLBSMN1; SMN2RXFP1 | |
| SCHEMBL13602070 | 0.77 | KDM5A (0.57) | NPC1RAB9APOLBSMN1; SMN2RXFP1 | |
| SCHEMBL3979968 | 0.73 | KDM4E (0.45) | NPC1RAB9ASMN1; SMN2RXFP1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1996553-A2 | TUMOR NECROSIS FACTOR ALPHA INHIBITORS AND THEIR USE IN THE TREATMENT OF HUMAN DISEASES | Avanir Pharmaceuticals (US) | 2008-12-03 | — | — | EP | disclosed |
| US-20080139551-A1 | TUMOR NECROSIS FACTOR ALPHA INHIBITORS AND THEIR USE IN THE TREATMENT OF HUMAN DISEASES | AVANIR PHARMACEUTICALS (US) | 2008-06-12 | — | — | US | disclosed |
| US-20080139551-A1 | TUMOR NECROSIS FACTOR ALPHA INHIBITORS AND THEIR USE IN THE TREATMENT OF HUMAN DISEASES | AVANIR PHARMACEUTICALS (US) | 2008-06-12 | — | — | US | disclosed |
| US-20080139551-A1 | TUMOR NECROSIS FACTOR ALPHA INHIBITORS AND THEIR USE IN THE TREATMENT OF HUMAN DISEASES | AVANIR PHARMACEUTICALS (US) | 2008-06-12 | — | — | US | disclosed |
| US-7365200-B2 | Thienopyridinone derivatives as macrophage migration inhibitory factor inhibitors | AVANIR PHARMACEUTICALS (US) | 2008-04-29 | — | — | US | disclosed |
| US-7365200-B2 | Thienopyridinone derivatives as macrophage migration inhibitory factor inhibitors | AVANIR PHARMACEUTICALS (US) | 2008-04-29 | — | — | US | disclosed |
| US-7365200-B2 | Thienopyridinone derivatives as macrophage migration inhibitory factor inhibitors | AVANIR PHARMACEUTICALS (US) | 2008-04-29 | — | — | US | disclosed |
| EP-1861407-A1 | THIENOPYRIDINONE DERIVATIVES AS MACROPHAGE MIGRATION INHIBITORY FACTOR INHIBITORS | AVANIR PHARMACEUTICALS (US) | 2007-12-05 | — | — | EP | disclosed |
| WO-2007109251-A2 | TUMOR NECROSIS FACTOR ALPHA INHIBITORS AND THEIR USE IN THE TREATMENT OF HUMAN DISEASES | AVANIR PHARMACEUTICALS (US) | 2007-09-27 | — | — | WO | disclosed |
| WO-2007109251-A2 | TUMOR NECROSIS FACTOR ALPHA INHIBITORS AND THEIR USE IN THE TREATMENT OF HUMAN DISEASES | AVANIR PHARMACEUTICALS (US) | 2007-09-27 | — | — | WO | disclosed |
| US-20070179149-A1 | THIENOPYRIDINONE DERIVATIVES AS MACROPHAGE MIGRATION INHIBITORY FACTOR INHIBITORS | AVANIR PHARMACEUTICALS (US) | 2007-08-02 | — | — | US | disclosed |
| US-20070179149-A1 | THIENOPYRIDINONE DERIVATIVES AS MACROPHAGE MIGRATION INHIBITORY FACTOR INHIBITORS | AVANIR PHARMACEUTICALS (US) | 2007-08-02 | — | — | US | disclosed |
| US-20070179149-A1 | THIENOPYRIDINONE DERIVATIVES AS MACROPHAGE MIGRATION INHIBITORY FACTOR INHIBITORS | AVANIR PHARMACEUTICALS (US) | 2007-08-02 | — | — | US | disclosed |
| US-20060229314-A1 | Thienopyridinone derivatives as macrophage migration inhibitory factor inhibitors | AVANIR PHARMACEUTICALS | 2006-10-12 | — | — | US | disclosed |
| WO-2006102191-A1 | THIENOPYRIDINONE DERIVATIVES AS MACROPHAGE MIGRATION INHIBITORY FACTOR INHIBITORS | AVANIR PHARMACEUTICALS (US) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179149-A1 | THIENOPYRIDINONE DERIVATIVES AS MACROPHAGE MIGRATION INHIBITORY FACTOR INHIBITORS | MIF, MMP12, MSR1 | NPC1 1125/4885RAB9A 1591/4885POLB 4430/4885 |
| US-20080139551-A1 | TUMOR NECROSIS FACTOR ALPHA INHIBITORS AND THEIR USE IN THE TREATMENT OF HUMAN DISEASES | TNF, TNFRSF1A, TNFRSF9 | NPC1 626/4885RAB9A 3433/4885POLB 1737/4885 |
| US-20060229314-A1 | Thienopyridinone derivatives as macrophage migration inhibitory factor inhibitors | MIF, MMP12, MSR1 | NPC1 1125/4885RAB9A 1591/4885POLB 4430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.